Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult over aged 50 years~* Menopause females or females who are confirmed to be negative in a preganacy test on the day of screening and agree to practice birth control for 6 weeks after signing informed concent~Exclusion Criteria:~* Those with hypersensitivity to any component of IP(Investigational Product), such as gelatin~* Those with a history of hypersensitivity to vaccination, such as Guillain-Barre syndrome~* Those who have received antiviral agents witin 1 month prior to IP vaccination (topical antiviral agent is allowed)~* Those who have previously received herpes zoster vaccine~* Those who have a history of herpes zoster~* Those with congenital or acquired immunodeficiency~* Those with active untreated tuberculosis~* Those who have received blood products or immunoglobulin within 3 months prior to IP(Investigational Products) vaccination~* Those who have received other IPs(Investigational Products) in another clinical study witin 4 weeks prior to IP vaccination in this study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NBP608 (Type: EXPERIMENTAL): Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm
- Zostavax (Type: ACTIVE_COMPARATOR): Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm

Based on this trial design, predict the completion outcome and termination type (if applicable).